Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalpiciclib and Pyrotinib in HER2-positive advanced breast cancer
NCT04293276Phase 2Unknown
- Sponsor
- Henan Cancer Hospital
- Start
- Apr 2020
- Primary completion
- Aug 2021
- Countries
- 1
01
Overview
A Phase 2 trial of dalpiciclib in HER2-positive breast cancer, breast cancer, sponsored by Henan Cancer Hospital. Status: unknown.
02
Drugs
dalpiciclib
03
Conditions
HER2-positive breast cancerbreast cancer
Beyond the preview
Go deeper on NCT04293276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04293276.